CLOVERBIO-B：ANNUALRESULTSANNOUNCEMENTFORTHEYEARENDEDDECEMBER312025ANDPROPOSEDAMENDMENTSTOTHEMEMORANDUMANDARTICLESOFASSOCIATION.pdf

《CLOVERBIO-B：ANNUALRESULTSANNOUNCEMENTFORTHEYEARENDEDDECEMBER312025ANDPROPOSEDAMENDMENTSTOTHEMEMORANDUMANDARTICLESOFASSOCIATION.pdf》由会员分享，可在线阅读，更多相关《CLOVERBIO-B：ANNUALRESULTSANNOUNCEMENTFORTHEYEARENDEDDECEMBER312025ANDPROPOSEDAMENDMENTSTOTHEMEMORANDUMANDARTICLESOFASSOCIATION.pdf（43页珍藏版）》请在三个皮匠报告上搜索。

1、 1 Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement,make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in rel

2、iance upon the whole or any part of the contents of this announcement.Clover Biopharmaceuticals,Ltd.三葉草生物製藥有限公司(Incorporated in the Cayman Islands with limited liability)(Stock Code:2197)ANNUAL RESULTS ANNOUNCEMENTFOR THE YEAR ENDED DECEMBER 31,2025 ANDPROPOSED AMENDMENTS TO THE MEMORANDUM AND ARTIC

3、LES OF ASSOCIATIONThe Board is pleased to announce the audited consolidated results of the Group for the Reporting Period,together with the comparative figures for the year ended December 31,2024.The consolidated financial statements of the Group for the Reporting Period have been reviewed by the Au

4、dit Committee and audited by the Companys auditor,Rongcheng(Hong Kong)CPA Limited(formerly known as CL Partners CPA Limited).In this announcement,“we”,“us”and“our”refer to the Company and where the context otherwise requires,the Group.Certain amounts and percentage figures included in this announcem

5、ent have been subject to rounding adjustments,or have been rounded to one or two decimal places.Any discrepancies in any table,chart or elsewhere between totals and sums of amounts listed therein are due to rounding.FINANCIAL HIGHLIGHTSAs of December 31,20252024RMB 000RMB 000Cash and bank balances27

6、1,403556,515 Year Ended December 31,20252024RMB 000RMB 000Revenue3,50538,419Other income and gains54,09897,215Selling and distribution expenses(5,070)(19,705)Administrative expenses(66,332)(75,172)Research and development expenses(182,338)(183,387)Other expenses(7,813)(738,201)Loss for the year(205,